Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment Available

The requested reference [3910554893f7a53bc9a8872025790265d0f1ae6c] no longer exists in our database. It has been replaced by the current reference: [a09c2851190f47023e24683b951d4bb7c6766310]

Authors
Category Primary study
ConferenceClinical cancer research
Year 2025
This article has no abstract
Epistemonikos ID: 0226494c668e2ce867f681982899564010fc521f
First added on: Jul 21, 2026